Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sanofi India's OCF Margin % or its related term are showing as below:
BOM:500674'
s OCF Margin % Range Over the Past 10 Years
Min: 11.63 Med: 16.13 Max: 24.04
Current: 24.71
During the past 13 years, the highest OCF Margin % of Sanofi India was 24.04%. The lowest was 11.63%. And the median was 16.13%.
BOM:500674's OCF Margin % is ranked better than 86.31% of 964
companies
in the Drug Manufacturers industry
Industry Median: 10.035
vs BOM:500674: 24.71
Sanofi India OCF Margin % Related Terms
Sanofi India OCF Margin % Historical Data
* Premium members only.
The historical data trend for Sanofi India's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500674 vs LLY, JNJ, ABBV: OCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Sanofi India's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi India OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi India's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Sanofi India's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi India (BOM:500674) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sanofi India and its competitors. Over the past decade, Sanofi India's OCF Margin % has ranged from 11.63 to 24.04. According to the industry distribution chart, Sanofi India ranks #132 out of 964 companies in the Drug Manufacturers industry, placing it in the top 13.7%.
Is Sanofi India's OCF Margin % too high?
Sanofi India's current OCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 11.63 to a high of 24.04. Based on the distribution chart, Sanofi India ranks #132 out of 964 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi India has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanofi India's OCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi India ranks #132 out of 964 companies for OCF Margin %. This places Sanofi India in the top 14% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 10.04. Historically, Sanofi India's own OCF Margin % has ranged from 11.63 to 24.04 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sanofi India and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi India's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi India stock overvalued right now?
Based on GuruFocus' analysis, Sanofi India (BOM:500674) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹4,402.68, compared to a current price of ₹3,369.25 — trading 23.5% below its estimated fair value. The current OCF Margin % is 0.00%. Sanofi India's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Sanofi India (BOM:500674), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi India (BOM:500674) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi India stock appears to be undervalued.
The current stock price of ₹3,369.25 is trading 23.5% below its estimated GF Value™ of ₹4,402.68.
GuruFocus considers Sanofi India to be Modestly Undervalued.
Key valuation signals for BOM:500674:
OCF Margin %: 0.00%
GF Value™: ₹4,402.68 vs. price of ₹3,369.25 (23.5% below fair value)
No single metric tells the full story. See the BOM:500674 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
77GF Score
Get the complete analysis for BOM:500674
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500674 has been successfully added to your 
